OMS302 + Placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
72
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Intraocular Lens Replacement
Conditions
Intraocular Lens Replacement
Trial Timeline
Sep 1, 2011 → Mar 1, 2012
NCT ID
NCT01454063About OMS302 + Placebo
OMS302 + Placebo is a phase 3 stage product being developed by Omeros Corporation for Intraocular Lens Replacement. The current trial status is completed. This product is registered under clinical trial identifier NCT01454063. Target conditions include Intraocular Lens Replacement.
Hype Score Breakdown
Clinical
27
Activity
18
Company
5
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01579565 | Phase 3 | Completed |
| NCT01454063 | Phase 3 | Completed |
Competing Products
6 competing products in Intraocular Lens Replacement
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Mirabegron + Placebo | Astellas Pharma | Phase 1 | 33 |
| AZD4017 + Placebo + AZD4017 + Placebo | AstraZeneca | Phase 2 | 52 |
| ipilimumab + Tyrosinase/gp100/MART-1 Peptides | Bristol Myers Squibb | Phase 2 | 51 |
| OMS302 + Placebo | Omeros Corporation | Phase 3 | 72 |
| Part 1 OMS302 + Part 2 OMS302 + Part 2 Placebo | Omeros Corporation | Phase 3 | 72 |
| cisplatin + sunitinib malate + tamoxifen citrate | Pacific Biosciences | Phase 2 | 44 |